...Candy Laura Steffen; Pelin Kaya; Elisabeth Schaffner-Reckinger; Daniel Abankwa RAS drug development has made enormous strides in the past ten years, with the first direct KRAS inhibitor being approved in 2021. However, despite the clinical success of covalent KRAS-G12C inhibitors, we...

... on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) . drug development drug discovery microfluidic models organ-on-a-chip Attrition rates have long been considered as the main cause of costs in drug development, which has been...

... published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND) . chemical probe drug development inhibitor post-translational modification PROTAC ubiquitin Ubiquitination is indispensable...

... ALK2 as a promising drug target. Beneficial effects of ALK2 inhibition have now been observed in two different in vivo models of DIPG. Nonetheless, such tumours present a huge challenge for traditional economic models of drug development due to their small market size, high failure rate, tumour...

... and not adaptable to all systems. Furthermore, pharmacological tools of the catalytic site are not optimal due to their non-selective nature. In the present brief review, we discuss some of the challenges in drug development that will regulate the multifunctional protein kinase Cδ (PKCδ). 1 To whom...

... has not been extensively explored and there is limited knowledge regarding the characteristics of CPPs which are necessary for drug development. A better understanding of the properties of CPPs relating to in vivo pharmacology, pharmacokinetics, pharmacodynamics and safety will continue to inform...

... for chemotherapy of microsporidia. 1 To whom correspondence should be addressed (e-mail cbacchi@pace.edu ). 678th Meeting of the Biochemical Society, held at Imperial College, London, 16–18 December 2002 28 November 2002 Copyright 2003 Biochemical Society 2003 drug development...